Selected References of the group members:
- Prof. Dr. Konrad Heintze
- Prof. Dr. Werner Winter
- Dr. Helmut Buschmann
- Dr. Elmar Friderichs
- Dr. Maren Kops (geb. Trost)
- Dr. Wolfgang Lintz
- Dr. Theo Matthiesen
- Dr. Eve C. A. Morgenstern
- Dr. Peter Kraahs
Prof. Dr. Konrad Heintze
authoring 4 assessment reports during my work at the BfArM
preparation of 5 CTDs
numerous expert reports
Kops M, Paulus W, Heintze K, Petersen K-U
Paracetamol: altbewährt oder riskant?
Deutsche Apotheker Zeitung (2011) 151(7): 68-72
Petersen KU, Labens J, Heintze K.
Pharmaka mit Wirkungen auf den Gastrointestinaltrakt.
Pharmakologie und Toxikologie, Ed. Estler CJ.
Schattauer Verlag, Stuttgart; p. 597 – 636; 6. Ed. (2007)
Schneider J, Friderichs E, Heintze K, et al.
Taprostene Sodium.
Cardiovascular Drug Reviews (1993) 11: 479-500
Riedel R, Bohnenkamp W, Eltze M, Heintze K; Prinz W, Kromer W.
Comparison of the gastric antisecretory and antiulcer potencies of telencepine and cimetidine in the rat.
Digestion. (1988) 40: 25-32
Heidenreich O, Greven J, Heintze K.
Molecular actions of diuretics.
Klin Wochenschr. (1982) 60: 1258-1263
Heintze K, Frizzell RA.
Electrogenic chloride secretion by mammalian colon.
Mechanisms of Intestinal Secretion, Ed. Binder HJ,
New York Alan Liss Inc. p. 101-110 (1979)
Gerloff J, Mignot A,. Barth H, Heintze K.
Pharmacokinetics and absolute bioavailability of lansoprazole.
Euro J Clin Pharmacol. (1979) 50: 293-297
Prof. Dr. Werner Winter
Winter W, Deubner R, Holzgrabe U.
Multivariate analysis of nuclear magnetic resonance data – characterization of critical drug substance quality of gentamicin sulphate.
J Pharm Biomed. Anal. (2005) 38: 833-839
Wnendt S, Finkam M, Winter W, Ossig J, Raabe G and Zwingenberger K.
Enantioselective Inhibition of TNF-a Release by Thalidomide and Thalidomide-Analogues.
Chirality (1996) 8: 390-396
Winter W and Frankus E.
Thalidomide enantiomers.
The Lancet (1992) 339: 365
Straßburger W, Winter W, Steffens GJ, Günzler WA and Flohé L.
Computer Aided Protein Design: Three Dimensional Model Building of the Saruplase Structure.
in Supercomputer and Chemistry 2, U. Harms (Ed.),
Springer-Verlag Berlin Heidelberg, (1991) S. 159-166
Winter W.
Naxaprostene.
Drugs of the Future (1990) 15: 233-236
Chiang Y, Krsge AJ, Seipp U and Winter W.
Kinetics of Hydrolysis of the Vinyl Ether Functional Group of the Stable Bioactive Prostacyclin Analogue Taprostene (CG 4203).
J Org Chem (1988) 53: 2552-2555
Bosch R, Jung G, Schmitt H, Sheldrick GM and Winter W.
Peptide Structures of the Alamethicin Sequence: The C-Terminal a/3 10 Helical Nonapeptide and Two Pentapeptides with Opposite 3 10 Helicity.
Angew Chem (1984) 23: 450-453
Winter W, Graudums I and Frankus E.
EPC-Synthese von (R)-(+)- und (S)-(-)-Supidimid und Kristallstrukturanalyse von (R)-(+)-Supidimid.
Liebigs Ann Chem (1983) 2021-2028
Dr. Helmut Buschmann
Wiese C, Große-Maestrup E, Schepmann D, Vela JM, Holenz J, Buschmann H, Wünsch B,
Pharmacological and metabolic characterisation of the potent 1 receptor ligand 1’–benzyl-3-methoxy-3H-spiro{[2]benzofuran-1,4’-piperidine},
Journal of Pharmacy and Pharmacology (2009) 61, in press.
Hamon M, Baeyens JM, Buschmann H, Vela J, et al.,
5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice,
Pain (2009) 141, p. 239-247.
Heal D J, Smith S L., Fisas, A, Codony X, Buschmann H,
Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders,
Pharmacology & Therapeutics (2008) 117(2), p. 207-231.
Buschmann H, Holenz J, Parraga A, Torrens A, Vela JM,
Antidepressants, Antipsychotics, Anxiolytics - From Chemistry & Pharmacology to Clinical Application, 2 Volumes, 1260 pages, Wiley-VCH, ISBN 3-527-31058-4 (2007)
Corbera J, Buschmann H, Holenz J, et al.,
A medicinal-chemistry-guided approach to selective and druglike sigma 1 ligands.
ChemMedChem (2006) 1(1), p. 140-154.
Fisas A, Buschmann H, Pauwels PJ, et al.,
Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats,
British Journal of Pharmacology (2006) 148(7), p. 973-983.
Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B,
Analgesics - From Chemistry & Pharmacology to Clinical Application, 604 pages, Wiley-VCH, ISBN 3-527-30403-7, (2002).
Christoph T, Buschmann H,
Two complex action principles in a single structure. Mixed opioid agonists-antagonists and partial agonists.
Pharmazie in unserer Zeit (2002), 31(1), p. 40-3.
Buschmann H, Sundermann B; Maul C,
Old and new µ-opioids. µ-selective opioids without morphinan structures,
Pharmazie in Unserer Zeit (2002) 31(1), p. 44-50.
Scharf H-D, Buschmann H,
Stereochemie in der Organischen Synthese: Reaktionen, Modelle, Konzepte,
libry, books on demand, 1. Auflage, 1002 pages, ISBN 3-89811-518-6, (2000)
Gais H-J; Griebel C, Buschmann H,
Enzymatic resolution of analgesics: -hydroxytramadol, -hydroxytramadol and O-desmethyltramadol.
Tetrahedron: Asymmetry (2000) 11(4), p. 917-928.
Buschmann H, Scharf, H-D, Hoffmann N, Esser P,
The isoinversion principle - A general selection model in chemistry.
Angewandte Chemie (1991) 103(5), p. 480-518 (See also Angew. Chem., Int. Ed. Engl., (1991) 30(5), p. 477-515).
Dr. Elmar Friderichs
Petersen KU, Friderichs E.
Paracetamol – klinischer Einsatz und neue Erkenntnisse zum analgetischen Wirkmechanismus,
Intensiv- und Notfallbehandlung (2010) 35(1): 16-25
Friderichs E, Christoph T, Buschmann H.
Analgesics and Antipyretics
In: Ullmann’s Encyclopedia of Industrial Chemistry
Wiley-VHC, Weinheim, p 1-97 (2007)
Friderichs E, et al.
Basic Pharmacology of Buprenorphine
In: Buprenorphine- The Unique Opioid Analgesic;
Pharmacology and Clinical Application.
Ed. K. Budd and R.B. Raffa,
Thieme Verlag, Stuttgart, New York, p. 3-21 (2005)
Friderichs E, Straßburger W.
Pharmakologie der Opioide
In: Praxis der transdermalen Schmerztherapie.
Unimed Verlag, International Medical Publishers, London , Boston, 2. Auflage, p. 25-42 (2004)
Buschmann H, Christoph T, Friderichs E, Maul C, Sundermann B
Analgesics - From Chemistry and Pharmacology to Clinical Application, 604 pages, Wiley-VCH, ISBN-3-527-30403-7 (2002).
Friderichs E, Straßburger W.
Opiatrezeptoren: Vom Schlüssel-Schloss-Modell zur molekularbiologischen Charakterisierung
Pharmazie in unserer Zeit (2002) 31: 32-39
Kögel B, Christoph E, Friderichs E, Hennies HH, Matthiesen T, Schneider J, Holzgrabe U.
HZ2, a selective kappa-opioid agonist.
CNS Drug Rev. (1998) 4: 54-70
Raffa, RB, Friderichs E
The basic science aspect of tramadol hydrochloride.
Pain Reviews (1996) 3:249-271
Schneider J, Friderichs E, Heintze K, et al.
Taprostene Sodium.
Cardiovascular Drug Reviews (1993) 11: 479-500
Dr. Maren Kops (geb. Trost)
Kops M, Paulus W, Heintze K, Petersen K-U
Paracetamol: altbewährt oder riskant?
Deutsche Apotheker Zeitung (2011) 151(7): 68-72
Kirshner, JR, Karpova, AY, Kops M, Howley PM
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.
J Virol. (2005) 79: 9320-9324
Karpova AY, Trost M, Murray JM, Cantley LC, Howley PM
Interferon regulatory factor-3 is an in vivo target of DNA-PK.
Proc Natl Acad Sci USA. (2002) 99: 2818-2823
Trost M, Kochs G, Haller O.
Characterization of a novel serine/threonine kinase associated with nuclear bodies.
J Biol Chem (2000) 275: 7373-7377
Dr. Wolfgang Lintz
Lintz W, Becker R, Gerloff J, Terlinden R.
Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations.
Arzneimittelforschung /Drug Research (2000) 50: 99-108
Lintz W, Beier H, Gerloff J.
Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion.
Int J Clin Pharmacol Ther. (1999) 37: 175-83
Lintz W.
Pharmacokinetic considerations for the setting of in-vitro models.
J Antimicrob Chemother. (1985) 15(Suppl A): 85-97
Lintz W, Hirsch I, Osterloh G, Schmidt-Böthelt E, Sous H.
Bioverfügbarkeit von Penicillin V in einer wäßrigen Zubereitungsform.
Arzneimittelforschung /Drug Research (1984) 34: 66-71
Lintz W, Erlaçin S, Frankus E, Uragg H.
Metabolismus von Tramadol bei Mensch und Tier.
Arzneimittelforschung /Drug Research (1981) 31: 1932-43
Dr. Theo Matthiesen
Matthiesen T, Wöhrmann T, Coogan TP, Uragg H.
A review of the experimental toxicology of tramadol.
Toxicology Letters. (1998) 95: 63-71
Gutser UT, Friese J, Heubach JF, Matthiesen T, Selve N, Wilffert B, Gleitz J.
Mode of antinociceptive and toxic action of alkaloids of Aconitum spec.
Arch Pharmacol. (1998) 357: 39-48
Kögel B, Christoph E, Friderichs E, Hennies HH, Matthiesen T, Schneider J, Holzgrabe U.
HZ2, a selective kappa-opioid agonist.
CNS Drug Rev. (1998) 4: 54-70
Harling RJ, Gopinath C, Matthiesen T, Ishibashi S, Iwakura K, Sumi N.
Four-week intravenous toxicity study of montirelin hydrate (NS-3) in dogs followed by 4-week recovery test.
J Toxicol Sci. (1995) 20 (Suppl 2): 215-236
Matthiesen T, Wöhrmann T.
Chlormadinonacetat: Aspekte zur Toxikologie.
In: E-G Loch, G Schramm (Hrsg).
Chlormadinonacetat bei Androgenisierungserscheinungen. Stellenwert in der Praxis;
Stuttgart, New York, p. 29 - 36 (1995)
Wöhrmann T, Kögel B-Y, Schneider J, Matthiesen T.
The beagle dog as a predictor of gastrointestinal findings in humans caused by the prostacyclin analogue taprostene.
Exp Toxic Pathol. (1994) 46: 71-73
Wöhrmann T, Matthiesen T, Beier H, Flohé L.
Immunhistochemical detection of Saruplase (recombinant single-chain urokinase-type plasminogen activator) in normal rat tissue.
Histochemistry. (1991) 96: 163-167
Schröder JM, Matthiesen Th.
Experimental thalidomide neuropathy: The morphological correlate of reduced conduction velocity.
Acta Neuropathol. (1985) 65: 285-292
Dr. Eve C. A. Morgenstern
Preparation of about 50 Expert Reports/ CTD Overviews/ Dossiers
Hoie, LH, Morgenstern ECA., Gruenwald J., Graubaum H-J, Busch R, Lüder W, Zunft H-JF
A double-blind, placebo controlled trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Soy phospholipids and fiber enhance the cholesterol-lowering effect of soy protein. European J. of Nutrition (2005) 44 (2): 65-71
Hermansen, K, Dinesen, B, Hoie, LH, Morgenstern, E, Gruenwald, J.
Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: A literature review. Advanced Therapeutics (2003) 20 (1): 50-78
Rex A, Morgenstern E, Fink H
Anxiolytic-like effects of Kava-Kava in the elevated plus maze test-a comparison with diazepam.
Progress of Pharmacology and Toxicology, 26 (2002) 26: 855-860
Morgenstern, E, Stattmann A, Grosse-Siestrup C, Stahl K, von Bayer H.
Ergebnisse zur pharmakologischen Untersuchung von Substanzen im Modell der physiologischen ex vivo-Hämoperfusion der isolierten Niere, pp 451-452. In: Forschung ohne Tierversuche 2000,
Schöffl H, Spielmann H, Gruber FP, Appl H, Harrer F, Pfaller W, Tritthart HA. Ersatz und Ergänzungsmethoden zu Tierversuchen, Ed. H. Schöffl, H. Spielmann und H. A. Tritthart. Springer-Verlag Wien, New York (2000)
Morgenstern, E
Die antiphlogistische Wirkung von Bronchipret® und seiner Komponenten im Rattenpfoten-Ödem-Modell. In: Bronchitis – Neue Erkenntnisse zu Wirkungen und Wirksamkeit von Arzneipflanzen.
Ed. R.W. März
Karger Verlag, Freiburg, 1-9 (1998)
Morgenstern, E
Bedeutung der Antazida
In: Antazida: vom "logischen Plazebo" zum differenzierten Medikament.
Ed. R. Arendt Und W. Rönsch
Univ.-Verlag, Jena, 24-45 (1993)
Voigt, J-P, Morgenstern E
Comparative effects of carbamazepine, phenytoin, diazepam and clonazepam on inhibitory avoidance learning in mice.
Psychopharmacology (1992) 108: 131-135
Morgenstern, E, Stattmann A
Wirkung von D-Phenylalanin im Vergleich zu DL-Phenylalanin in ausgewählten Analgesiemodellen am Tier.
In: Beitr. Wirkstofforsch. Ed. P. Oehme, H. Löwe, E. Göres, Berlin, 36, 210-214 (1990)
Morgenstern, E, Voigt J-P
Similar actions of lithium chloride and some antiepileptics.
Neuroscience (1987) 22 (Suppl.): 666
Hempel R, Heidenbluth K, Dauth Ch, Bartsch R, Schmidt J, Rostock A, Hoffmann W, Morgenstern E
Neue nootrop wirksame Ergoline.
Schriftenreihe med. Akad. "Carl-Gustav-Carus", Dresden, (1986) 22 B: 273-277
Morgenstern, E, Grimmberger M
Klinisches Wirkungsspektrum von Valproinsäure (Convulsofin)
Medicamentum (1986) 8: 175-182
Oehme, P, Hilse H, Morgenstern E, Göres E
Substance P: Does it produce Analgesia or Hyperalgesia?
Science(1980) 208:
Dr. Peter Kraahs (geb. Schultz)
Schultz P, Kleinebudde P
Determination of pellet friability by use of an air stream apparatus
Pharm. Ind., (1995) 57: 323 – 328
Schultz P, Kleinebudde P
A new multiparticulate delayed release system
Part I: Dissolution properties and release mechanism
Part II: Coating formulation and properties of free films
J. Contr. Rel. (1997) 47: 181-199
Kraahs P
The compression of enteric coated pellets
APV Seminar, Bielefeld 2003
Kraahs P
Optimization of bioavailability by dosage form design
6th Scientific & Technical Forum „Trends in Formulation Design“, Basel 2009
Rodriguez M, Lucas J, Kraahs P
Formulation and dose equivalence for Paracetamol stick pack across studies using population pharmacokinetic methods;
7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Malta 2010
Rodriguez M, Lucas J, Knapp A, Kraahs P
Modelling and literature analysis to evaluate the pharmacokinetics of new fast release Ibuprofen based on a comparison of studies performed in India and Europe
World Pharma, Kopenhagen 2010
Stegemann S, Ecker F, Maio M, Kraahs P, Wohlfart R, Breitkreutz J, Zimmer A, Bar-Shalom D, Hettrich P, Broegmann B.
Geriatric drug therapy: Neglecting the inevitable majority
S. Stegemann et al.,
Ageing Res Rev. 2010 Oct; 9(4): 384-98.
